Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Aug 30;293(6546):515–516. doi: 10.1136/bmj.293.6546.515

Low dose maintenance medication for schizophrenia.

R Manchanda, S R Hirsch
PMCID: PMC1341296  PMID: 2875757

Full text

PDF
515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldessarini R. J., Davis J. M. What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res. 1980 Oct;3(2):115–122. doi: 10.1016/0165-1781(80)90028-1. [DOI] [PubMed] [Google Scholar]
  2. Hirsch S. R., Gaind R., Rohde P. D., Stevens B. C., Wing J. K. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J. 1973 Mar 17;1(5854):633–637. doi: 10.1136/bmj.1.5854.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hogarty G. E. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective. J Clin Psychiatry. 1984 May;45(5 Pt 2):36–42. [PubMed] [Google Scholar]
  4. Hogarty G. E., Ulrich R. F. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry. 1977 Mar;34(3):297–301. doi: 10.1001/archpsyc.1977.01770150055005. [DOI] [PubMed] [Google Scholar]
  5. Johnson D. A. Antipsychotic medication: clinical guidelines for maintenance therapy. J Clin Psychiatry. 1985 May;46(5 Pt 2):6–15. [PubMed] [Google Scholar]
  6. Johnson D. A. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry. 1979 Dec;135:524–530. doi: 10.1192/bjp.135.6.524. [DOI] [PubMed] [Google Scholar]
  7. Johnson D. A., Pasterski G., Ludlow J. M., Street K., Taylor R. D. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983 May;67(5):339–352. doi: 10.1111/j.1600-0447.1983.tb00351.x. [DOI] [PubMed] [Google Scholar]
  8. Kane J. M., Rifkin A., Woerner M., Reardon G., Sarantakos S., Schiebel D., Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983 Aug;40(8):893–896. doi: 10.1001/archpsyc.1983.01790070083010. [DOI] [PubMed] [Google Scholar]
  9. Marder S. R., Van Putten T., Mintz J., McKenzie J., Lebell M., Faltico G., May P. R. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry. 1984 Nov;41(11):1025–1029. doi: 10.1001/archpsyc.1983.01790220015002. [DOI] [PubMed] [Google Scholar]
  10. Teicher M. H., Baldessarini R. J. Selection of neuroleptic dosage. Arch Gen Psychiatry. 1985 Jun;42(6):636–637. doi: 10.1001/archpsyc.1985.01790290118019. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES